Cydectin TriclaMox

1 x 1 l

Oral solution

Active substance

Triclabendazole : 50 mg/ml

Moxidectin : 1 mg/ml

ATC code

QP54AB52 Moxidectin, comb.

QP54AB Milbemycins

QP54A Macrocyclic lactones

QP54 Endectocides

QP Antiparasitic products, insecticides and repellents

Species

Sheep

Indications

For the treatment of mixed nematode and fluke infections, caused by moxidectin and triclabendazole sensitive strains of:

Parasite	Adult stage	L4	Inhibited stages
NEMATODES
Gastro-intestinal nematodes:
Haemonchus contortus	•	•	•
Teladorsagia circumcincta	•	•	•
Ostertagia trifurcata	•	•
Trichostrongylus axei	•	•	•
Trichostrongylus colubriformis	•	•
Trichostrongylus vitrinus	•	•
Nematodirus battus	•	•
Nematodirus spathiger	•	•
Nematodirus filicolis	•
Strongyloides papillosus		•
Cooperia curticei	•
Cooperia oncophora	•	•
Oesophagostomum columbianum	•	•
Oesophagostomum venulosum	•
Chabertia ovina	•	•
Trichuris ovis	•
Respiratory tract nematode:
Dictyocaulus filaria	•
TREMATODES
Liver fluke:	Adult stage	Early Immature stages	Late Immature stages
Fasciola hepatica	•	•	•

The product has a persistent efficacy and protects sheep against infection or re-infection with the following parasites for the period indicated:

Species	Protection period (days)
Teladorsagia circumcincta	35
Haemonchus contortus	35

Clinical trials, after experimental and natural infection, have shown that the product is effective against certain benzimidazole resistant strains of:

. Haemonchus contortus

. Teladorsagia circumcincta

. Trichostrongylus colubriformis

. Cooperia curticei

Dose to be administered and administration route

Oral use.

Should be given as a single oral drench of 1 ml/5 kg bodyweight, equivalent to 0.2 mg moxidectin/kg bodyweight and 10 mg triclabendazole/kg bodyweight, using any standard drenching equipment.

To ensure a correct dosage, body weight should be determined as accurately as possible; accuracy of the dosing device should be checked. If animals are to be treated collectively rather than individually, they should be grouped according to their body weight and dosed accordingly, in order to avoid under- or overdosing.

Adverse reactions

None known.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also the section “Contact Details” of the package leaflet.